Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01085214 · ClinicalTrials.gov registry record · Phase 2
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT01085214: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01085214 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01085214, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01085214
The ClinicalTrials.gov registry entry for NCT01085214 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01085214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01085214 about?
NCT01085214 is a clinical study titled "AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma". This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.
What is the current status of trial NCT01085214?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2010-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01085214?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT01085214?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.